Kemwell Announces Successful USFDA Inspection
News Mar 27, 2015
Kemwell Biopharma Pvt. Ltd. has announced that its oral solids manufacturing facility located in Bangalore, India has successfully completed its second U.S. Food and Drug Administration (USFDA) inspection. This audit took place for an ANDA filed for a customer.
On completion of the inspection, the USFDA inspector concluded that the facility, systems and practices comply with USFDA requirements and no observations were reported on Form 483.
“Kemwell’s team is proud of the results of the FDA inspection. This success is testament to our ongoing commitment towards our quality systems. We continue to leverage our 30-year experience in being a leading CDMO to provide our customers with cost-effective solutions at high quality standards.” says Anurag Bagaria, Chairman and Managing Director.
The oral solids facility started cGMP production in 2008 and is designed to produce 5 billion tablets and capsules annually. The facility has high flexibility built-in to manage batch sizes ranging from 10kg to 1000kg. Kemwell has been regularly shipping products to Europe, Australia, Canada and USA from this facility.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE